Year: 2009
Type: letter
Abstract: On behalf of my coauthors, I wish to thank Chamberlain 1 for the important issues he raised regarding our recently reported trial, 2 in which patients with glioblastoma (GBM) were randomly assigned at first recurrence to receive single-agent cilengitide, an v 3 / v 5 integrin inhibitor, at either 500 mg or 2,000 mg twice weekly. The first important question raised by Chamberlain was why we chose to design our study to evaluate outcome against that reported with temozolomide, 3 rather than outcomes reported in a series of salvage phase II studies. We chose the comparative benchmark achieved with temozolomide for two reasons. First, a more favorable outcome was achieved in the temozolomide study, thus setting a higher bar of comparison. Second, our study, like the temozolomide study, was limited to patients with GBM at first recurrence, in contrast to the series of phase II studies suggested by Chamberlain, which included patients with disease that had progressed beyond first recurrence.
Source: Journal of Clinical Oncology
Author: David A. Reardon
Institution: Duke Medical Center
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4253825146